期刊文献+

尿毒症毒素与心脏损伤的再认识 被引量:10

New insight into the uremic toxins and cardiac injury
下载PDF
导出
摘要 心血管疾病(CVD)是慢性肾脏病(CKD),尤其是终末期肾病患者最常见的并发症及死亡原因之一。近年来,研究证实CKD患者及血液透析(HD)患者发生CVD及全因死亡率与蛋白结合毒素的蓄积密切相关。蛋白结合毒素是一类很难通过单纯HD清除的物质,大部分分子质量大于500 Da,与蛋白结合后导致蛋白自身分子结构、电荷甚至功能发生变化,抑或可能导致其他组织、器官损伤。目前研究相对较多的是同型半胱氨酸、硫酸吲哚酚、硫酸对甲酚等物质对肾脏及心血管的毒性,其可能的致病机制包括刺激内皮细胞或白细胞产生自由基,影响内皮细胞和白细胞的相互作用,损伤内皮细胞,促进血管平滑肌细胞增殖,导致动脉粥样硬化、心脏的纤维化等。 Cardiovascular disease (CVD) , the most common complication for chronic kidney disease, especially in patients with end-stage renal disease, but also is the leading cause of death. Recently, the protein-bound uremic toxins have been demonstrated that closely interrelated with cardiovascular mortality in CKD and/or dialysis patients. The protein- bound uremic toxins, the uremic toxics combined with albumin, most of them have an molecular weight (MW) 〉500 Da, which are poorly removed by currently standard dialysis strategies, may lead to the great change of the protein molecular structure itself, or even the function and the electricity, as well as injures to other organs or systems. More and more studies have demonstrated that the protein-bound uremic toxins, especially homocysteine, indoxyl sulfate and p-cresyl sulfate induce endothelial dysfunction and leukocyte activation, causing high oxidative stress. They also adversely affect the interaction between leukocytes and endothelium. Vascular smooth muscle cell (VSMC) prohferation, increased risk of atherosclerosis, and cardiac fibrosis may together explain the cardiovascular and renal toxicity of these protein-bound uremic toxins.
出处 《肾脏病与透析肾移植杂志》 CSCD 北大核心 2015年第2期160-164,共5页 Chinese Journal of Nephrology,Dialysis & Transplantation
关键词 尿毒症 毒素 心血管疾病 发病机制 uremic toxins cardiovascular disease pathogenesis
  • 相关文献

参考文献35

  • 1Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins : classification, concentration, and interindividual variability. Kidney Int,2003,63(5) : 1934-1943.
  • 2Neirynck N, Vanholder R, Schepers E, et al. An update on uremic toxins.Int Urol Nephrol,2013,45( 1 ) :139-150.
  • 3Glorieux G, Vanholder R.New uremic toxins-which solutes should be removed? Contrib Nephrol, 2011,168 : 117-128.
  • 4Niwa T, Takeda N, Tatematsu A, et al. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface revemed-phase liquid chromatography.Clin Chem, 1988,34 ( 11 ) :2264-2267.
  • 5Rttster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol, 2006, 17 (11) :2985-2991.
  • 6Lekawanvijit S, Kompa AR, Wang BH, et al.Cardiorenal syndrome : the emerging role of protein-bound uremic toxins. Circ Res, 2012, 111 ( 11 ) : 1470-1483.
  • 7陈斌,李艳华,刘杨.尿毒症毒素研究进展[J].吉林医学,2013,34(22):4513-4515. 被引量:13
  • 8Ueno H, Koyama H, Tanaka S, et al. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism, 2008,57(10) : 1452-1457.
  • 9Mallipattu SK, Uribarri J. Advanced glycation end product accumulation:a new enemy to target in chronic kidney disease? Curt Opin Nephrol Hypertens,2014,23(6) :547-554.
  • 10Balsam A, E1 Kossi MM, Lord R, et al. Cardiovascular disease on hemodialysis : predictors of atherosclerosis and survival. Hemodial Int, 2009.13 ( 3 ) : 278-285.

二级参考文献84

  • 1袁方,刘尚喜,侯凡凡,陈瑗,田建伟,刘志强.晚期氧化蛋白产物导致血管内皮细胞氧化应激损伤[J].解放军医学杂志,2004,29(11):951-954. 被引量:20
  • 2王国平,邓仲端,瞿智玲.氧化修饰的低密度脂蛋白和极低密度脂蛋白对单核细胞MCP-1表达的影响[J].中华病理学杂志,1996,25(4):220-223. 被引量:13
  • 3王国平.MCP-1及其基因的结构和功能[J].国外医学(生理病理科学与临床分册),1996,16(2):67-69. 被引量:5
  • 4Witko-Sarsat V,Fedlander M,Capeiltere-Blandin C,et al.Advanced oxidation protein products as a novel marker of oxidative stress in uremia.Kidney Int,1996,49(5):1304
  • 5Witko-Sarsat V,Friedlander M,Nguyen AT,et al.Advanced oxidation protein products as novel mediators of inflammation and monocyle activation in chronic renal failure.J Immunol,1998,161(5):2524
  • 6Witk-Sarsat V,Gausson V,Nguyen AT et al.AOPP induced activation of human neutrophil and monocyte oxidative metabolism:A potential target for N acetylcysteine treatment in dialysis patients.Kidney Int,2003,64(1):82
  • 7Kaneda H,Taguchi J,Ogasawara K,et al.Increased level of advanced oxidation protein products in patients with coronary artery disease.Atherosclerosis,2002,162(1):221
  • 8Drueke T,Witk-Sarsat V,Massy Z,et al.Iron therapy,advanced oxidation protein products,and carotid artery intima media thickness in end stage renal disease.Circulation,2002,106(17):2212
  • 9Descamps-Latscha -B,Jungers -P,Witko-Sarsat -V.Immune system dysregulation in uremia:Role of oxidative stress.Blood-Purif,2002,20 (5):481-484
  • 10Witko-Sarsat -V,Gausson -V,Descamps-Latscha -B.Are advanced oxidation protein products potential toxins? Kidney-Int-Suppl,2003,(84):S11-14

共引文献15

同被引文献111

引证文献10

二级引证文献96

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部